TAGCyx Biotechnologies
Tokyo
About TAGCyx Biotechnologies
TagCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. The Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $13.2M
- Last round: Series Unknown (Jul 2021)
- Website: tagcyx.comen
- Phone: +81-3-6407-1672
Industries & Categories
Biotechnology, Environmental Consulting, Nuclear
Social Profiles
Canonical: https://fsome.com/organization/tagcyx-biotechnologies-24472 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.